Politics and expertise: How to use science in a democratic society
By Zeynep Pamuk,
LSE European Politics and Policy Blog
| 03. 30. 2022
The Covid-19 pandemic has underlined the importance of scientific advice to modern policymaking. But how can the use of expertise in politics be aligned with the needs and values of the public? Drawing on a recent book, Zeynep Pamuk sets out a new model for the relationship between science and democracy.
The Covid-19 pandemic has put scientific advisory bodies under the spotlight as rarely before. The question of how scientific advisers should communicate their guidance in the face of wavering trust in science and scientists has subsequently received much scholarly and public attention over the past two years. But while the focus on scientific advice is certainly important, there is a limit to how far the problems in the relationship between science and politics can be fixed at the advisory stage.
After all, advisers are constrained by the knowledge available to them. Their recommendations depend on earlier decisions about which scientific questions should be pursued and how. To improve the relationship between science and democracy and ensure more effective responses to issues such as pandemics and climate change, we must...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...